AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017
May 24, 2017
31868_dirs_2017-05-24_347ecd05-ec27-43fc-b3d8-38cb1c25efbb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-05-22
Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-05-22 | Common Stock | M | 7750 | $4.73 | Acquired | 149210 | Direct |
| 2017-05-22 | Common Stock | F | 6996 | $5.24 | Disposed | 142214 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-05-22 | Emp. Stock Option (Right to Buy) | $4.73 | M | 7750 | Disposed | 2022-03-01 | Common Stock (7750) | Direct |
Footnotes
F1: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.
More from BIOCRYST PHARMACEUTICALS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20